Evidence map›Paper›PMID 42131817›Full record

ReviewFrontiers in pharmacology2026

The zebrafish model: a versatile platform for uncovering the therapeutic potential of phytochemicals in liver diseases.

Yuliang Liu, Xiang Meng, Wei Zhang, Mengmeng Sun, Ziyoviddin Yusupov, Komiljon Tojibaev, Kobil A Bobokalonov, Zhenghai Zhang, Min He, Meiying Jin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuliang LiuChangchun University of Chinese Medicine, Changchun, China.
Xiang MengChangchun University of Chinese Medicine, Changchun, China.
Wei ZhangChangchun Stomatological Hospital, Changchun, China.
Mengmeng SunChangchun University of Chinese Medicine, Changchun, China.
Ziyoviddin YusupovInstitute of Botany, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan.
Komiljon TojibaevInstitute of Botany, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan.
Kobil A BobokalonovInstitute of Botany, Plant Physiology and Genetics, National Academy of Tajikistan, Dushanbe, Tajikistan.
Zhenghai ZhangCollege of Chinese Materia Medica, Jilin Agricultural Science and Technology University, Jilin, China.
Min HeChangchun University of Chinese Medicine, Changchun, China.
Meiying JinChangchun University of Chinese Medicine, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for novel therapeutics for prevalent liver diseases such as metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and drug-induced liver injury is constrained by the methodological gaps in conventional preclinical models, which struggle to balance physiological complexity with screening efficiency. This challenge is particularly acute for natural products, where elucidating multifaceted mechanisms and inherent toxicological risks is paramount for translation. The zebrafish (

Indexed as

drug discoveryhepatoprotectionhepatotoxicityliver diseasephytochemicalszebrafish model

Identifiers

PMID42131817
PMCPMC13161132

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.